Metabolite Changes in the Zebrafish Model of Fetal Alcohol Spectrum Disorder Associated with Established Neural Abnormalities
Christine E.M. Keller,Maria S Sepúlveda,Amber Hopf Jannasch,Ali M Roumani,Feng C Zhou,Paul B Brown
DOI: https://doi.org/10.1096/fasebj.31.1_supplement.792.1
2017-01-01
The FASEB Journal
Abstract:Fetal alcohol spectrum disorder (FASD) is a completely preventable disease, that has profound effects on life‐long health and function of the affected individual. FASD is caused by maternal ethanol intake during pregnancy. The relationship between ethanol dose, consumption frequency, and the effects on the offspring are altered by the woman's health, fasted or non‐fasted state, and individual metabolism differences. Further, many women consume alcohol in early pregnancy, before they know they are pregnant, and the social stigma surrounding alcohol consumption during pregnancy may make self‐reporting less accurate. Because of the need for early intervention to minimize the effects of alcohol on the offspring, especially until a consensus on recommended limits on alcohol is achieved, early detection and improved characterization of the mechanisms involved in FASD etiology is key. To that end, we pursued a non‐targeted metabolomics approach to develop a more comprehensive profile of small molecule changes in FASD and found many metabolites that broaden the existing theories of neural modifications. AB strain zebrafish embryos were exposed to 0—3% ethanol from 2—24 hours post fertilization. After washing with media, the embryos were incubated an additional 24 hours, at which time they were flash frozen, and whole embryos were extracted. Non‐polar metabolites were separated using Agilent 1100 liquid chromatography with Thermo Fisher LTQ Orbitrap detection, and polar metabolites were analyzed using an Agilent 6220 TOF LC‐MS. From this data, we generated a profile of significantly altered metabolites changed with ethanol. Glycerophospholipids, including phosphatidylserine, phosphatidic acid, phosphatidylethanol, and phosphatidylinositol, are modified with ethanol exposure and showed varied directional and magnitudinal changes in our model. Similarly, ethanol‐induced changes occurred in ceramides and sphingolipids, as well as bile acids. These metabolite changes have known implications to astroglial proliferation and alterations to myelin and axon structure and development, and cell death. Together, these metabolite alterations provide an important broadening of molecules associated with well‐established neural abnormalities present in FASD, underscoring the vast and complicated nature of FASD. These changes in neural‐related metabolites have important implications for our understanding and development of interventions of FASD. Support or Funding Information Support was provided by the Indiana Clinical and Translational Sciences Institute to PB, MSS, and FCZ.